[Short- and medium-term tolerance of hypofractionated prostate radiotherapy with simultaneous integrated boost].

Laurène Larrivière, Stephane Supiot, Astrid Thomin, Simon Jan, Sofia Bakkar, Gilles Calais
{"title":"[Short- and medium-term tolerance of hypofractionated prostate radiotherapy with simultaneous integrated boost].","authors":"Laurène Larrivière, Stephane Supiot, Astrid Thomin, Simon Jan, Sofia Bakkar, Gilles Calais","doi":"10.1016/j.canrad.2024.04.004","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This retrospective study was conducted to ensure that irradiation of the pelvic lymph node areas associated with simultaneous hypofractionated boost to the prostate according to the protocol implemented at the university hospital of Tours (France) does not result in excess urinary and digestive toxicity in the short and medium term.</p><p><strong>Materials and methods: </strong>The study population included patients with localized unfavourable intermediate or high-risk prostate cancer. The dose delivered was 65Gy in 25 fractions of 2.6Gy to the prostate and seminal vesicles, and 50Gy in 25 fractions of 2Gy to the pelvic lymph nodes. Acute toxicity events (between the start of radiotherapy and the first follow-up consultation) and medium-term toxicity events (after the first follow-up consultation) were assessed using the CTCAE version 5.0 classification.</p><p><strong>Results: </strong>Sixty-three patients were treated according to the protocol between January 1st, 2020, and October 31st, 2022. The majority of them had high-risk prostate cancer (79%). The median follow-up was 15 months. Very few patients reported grade 3-4 toxicity acutely (6% urinary and 0% digestive toxicity) or in the medium term (7% urinary and 0% and digestive toxicity).</p><p><strong>Conclusion: </strong>Radiotherapy of pelvic lymph node areas with simultaneous hypofractionated boost to the prostate is feasible, with low rates of severe acute and medium-term toxicity.</p>","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.canrad.2024.04.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: This retrospective study was conducted to ensure that irradiation of the pelvic lymph node areas associated with simultaneous hypofractionated boost to the prostate according to the protocol implemented at the university hospital of Tours (France) does not result in excess urinary and digestive toxicity in the short and medium term.

Materials and methods: The study population included patients with localized unfavourable intermediate or high-risk prostate cancer. The dose delivered was 65Gy in 25 fractions of 2.6Gy to the prostate and seminal vesicles, and 50Gy in 25 fractions of 2Gy to the pelvic lymph nodes. Acute toxicity events (between the start of radiotherapy and the first follow-up consultation) and medium-term toxicity events (after the first follow-up consultation) were assessed using the CTCAE version 5.0 classification.

Results: Sixty-three patients were treated according to the protocol between January 1st, 2020, and October 31st, 2022. The majority of them had high-risk prostate cancer (79%). The median follow-up was 15 months. Very few patients reported grade 3-4 toxicity acutely (6% urinary and 0% digestive toxicity) or in the medium term (7% urinary and 0% and digestive toxicity).

Conclusion: Radiotherapy of pelvic lymph node areas with simultaneous hypofractionated boost to the prostate is feasible, with low rates of severe acute and medium-term toxicity.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[前列腺低分次同步综合增强放疗的短期和中期耐受性]。
目的:本项回顾性研究旨在确保根据图尔大学医院(法国)实施的方案对盆腔淋巴结区域进行照射并同时对前列腺进行低分量照射不会在中短期内导致过多的泌尿和消化系统毒性:研究对象包括局部不理想的中度或高度危险前列腺癌患者。前列腺和精囊的放射剂量为 65Gy,25 次分次放射,每次 2.6Gy;盆腔淋巴结的放射剂量为 50Gy,25 次分次放射,每次 2Gy。急性毒性事件(放疗开始至首次复诊期间)和中期毒性事件(首次复诊后)采用 CTCAE 5.0 版分类进行评估:在2020年1月1日至2022年10月31日期间,63名患者按照方案接受了治疗。其中大多数患者患有高风险前列腺癌(79%)。中位随访时间为 15 个月。极少数患者报告了3-4级急性毒性(6%为泌尿系统毒性,0%为消化系统毒性)或中期毒性(7%为泌尿系统毒性,0%为消化系统毒性):结论:对盆腔淋巴结区进行放疗,同时对前列腺进行低分次照射是可行的,急性和中期严重毒性发生率较低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Erratum to "Voice quality after surgery or radiotherapy for glottic T1 squamous cell carcinoma: Results of the VOQUAL study" [Cancer Radiother. 28 (2024) 373-379]. [Short- and medium-term tolerance of hypofractionated prostate radiotherapy with simultaneous integrated boost]. Outcomes of adjuvant lymph node field radiotherapy and immunotherapy for stage III melanoma. Pattern of relapse following three-field lymphadenectomy of esophageal carcinoma and related factors predictive of recurrence High-dose salvage re-irradiation in recurrent/progressive adult diffuse gliomas: development of a novel prognostic scoring system.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1